Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma

Li, J and Zhu, S and Kozono, D and Ng, K and Futalan, D and Shen, Y and Akers, JC and Steed, T and Kushwaha, D and Schlabach, M and Carter, BS and Kwon, C and Furnari, F and Cavenee, W and Elledge, S and Chen, CC (2014) Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget. pp. 882-893.

Abstract

Glioblastoma remains one of the deadliest of human cancers, with most patients succumbing to the disease within two years of diagnosis. The available data suggest that simultaneous inactivation of critical nodes within the glioblastoma molecular circuitry will be required for meaningful clinical efficacy. We conducted parallel genome-wide shRNA screens to identify such nodes and uncovered a number of G-Protein Coupled Receptor (GPCR) neurotransmitter pathways, including the Dopamine Receptor D2 (DRD2) signaling pathway. Supporting the importance of DRD2 in glioblastoma, DRD2 mRNA and protein expression were elevated in clinical glioblastoma specimens relative to matched non-neoplastic cerebrum. Treatment with independent si-/shRNAs against DRD2 or with DRD2 antagonists suppressed the growth of patient-derived glioblastoma lines both in vitro and in vivo. Importantly, glioblastoma lines derived from independent genetically engineered mouse models (GEMMs) were more sensitive to haloperidol, an FDA approved DRD2 antagonist, than the premalignant astrocyte lines by approximately an order of magnitude. The pro-proliferative effect of DRD2 was, in part, mediated through a GNAI2/Rap1/Ras/ERK signaling axis. Combined inhibition of DRD2 and Epidermal Growth Factor Receptor (EGFR) led to synergistic tumoricidal activity as well as ERK suppression in independent in vivo and in vitro glioblastoma models. Our results suggest combined EGFR and DRD2 inhibition as a promising strategy for glioblastoma treatment

Item Type: Article
Additional Information: NIBR author: Schlabach, M institute: NIBR contributor address: (Li, Ng, Futalan, Shen, Akers, Steed, Carter, Chen) Center for Translational and Applied Neuro-oncology, Division of Neurosurgery, University of California, San Diego, CA, United States (Zhu, Kozono, Kushwaha) Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States (Schlabach) Novartis Institutes for BioMedical Research, Cambridge, MA, United States (Kwon) Department of Neurological Surgery and Solid Tumor Program, Ohio State University Medical Center, Columbus, OH, United States (Furnari, Cavenee) Ludwig Institute for Cancer Research, La Jolla, CA, United States (Elledge) Department of Genetics, Harvard Medical School, Boston, MA, United States
Date Deposited: 13 Oct 2015 13:12
Last Modified: 13 Oct 2015 13:12
URI: https://oak.novartis.com/id/eprint/22626

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.